Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has land­ed a new first from UNICEF the first-ever con­tract for malar­ia vac­cines, worth up to $170 mil­lion for 18 mil­lion vac­cine dos­es dis­trib­uted over the next three years.

The vac­cine, known as Mosquir­ix or RTS,S, won WHO’s back­ing last Oc­to­ber af­ter a con­tro­ver­sial start, but UNICEF said these dos­es will po­ten­tial­ly save thou­sands of lives every year.

“We hope this is just the be­gin­ning,” Etl­e­va Kadil­li, di­rec­tor of UNICEF’s sup­ply di­vi­sion, said. “Con­tin­ued in­no­va­tion is need­ed to de­vel­op new and next-gen­er­a­tion vac­cines to in­crease avail­able sup­ply, and en­able a health­i­er vac­cine mar­ket. This is a gi­ant step for­ward in our col­lec­tive ef­forts to save chil­dren’s lives and re­duce the bur­den of malar­ia as part of wider malar­ia pre­ven­tion and con­trol pro­grammes.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA